Resource Library

A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical

In this episode of Px Pulse, the Dapivirine Vaginal Ring is center stage. After decades of research and advocacy, the ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in…

Community/Advocacy

After The Ring Study: DREAM

DREAM, or Dapivirine Ring Extended Access and Monitoring, was a year long open-label extension (OLE) study launched by the International Partnership for Microbicides (IPM) in 2019 to assess how safe the ring is for the 940 HIV- women who participated in The Ring Study, and explores when, why, and how women use the ring.

Community/Advocacy

Safety, Adherence and HIV-1 Seroconversion in DREAM – An Open-label Dapivirine Vaginal Ring Trial

The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article features a report on the DREAM study, which aimed to evaluate safety, adherence,…

Research

Final Results of Open-label Study of IPM’s Dapivirine Vaginal Ring Show Increased Use and Suggest Lower Infection Rates Compared to Earlier Phase III Study

This letter from the International Partnership for Microbicides outlines the results of an open-label study on the Dapivirine Vaginal Ring

Research

Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it

This article from the Microbicide Trials Network shares the results of an open-label study of a vaginal ring for HIV prevention

Community/Advocacy, Demand Creation/Marketing, Research

Adherence to the Dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study

Adolescent girls and young women (AGYW) account for most new HIV infections in sub-Saharan Africa. WHO has endorsed oral PrEP and dapivirine vaginal ring (ring) for women at substantial risk of HIV infection. However, adherence to both products was lower among younger women in randomized placebo-controlled trials. The authors of this article assessed interim safety,…

Research

Microbicide Trials Network-042 – DELIVER Study

Microbicide Trials Network-042/DELIVER is a Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring and oral PrEP in pregnant women.

Research

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Community/Advocacy

CHARISMA Mobile: Developing a digital resource for empowerment counseling, community health clinic model for agency in relationships and safer microbicide adherence

CHARISMA is a PEPFAR- and USAID-funded empowerment counseling intervention designed to help women use oral pre-exposure prophylaxis and other antiretroviral-based HIV prevention technologies safely and effectively by addressing dynamics of their relationships with male partners, including exposure to intimate partner violence. The intervention, designed to be delivered by lay counselors, is being adapted into a…

Research, Service Delivery

Stakeholder Conversations to Inform Delivery of New HIV Prevention Methods in South Africa

Little is known about what is needed for health care providers to ensure adequate counseling on method choice, referral mechanisms, and supportive follow-up with regards to multiple biomedical HIV prevention methods. The goal of these conversations with stakeholders in South Africa was to gain input on implementation considerations from provider and potential end-user perspectives, as…